A Phase 2 interventional study of Placebo and Nipocalimab in Sjogren's Syndrome, sponsored by Janssen Research & Development, LLC. Completed at 69 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.
Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 23rd largest by enrollment of the 76 interventional ones that give a count, is one of 10 that started in 2021, is one of 30 in phase 2, and was the 81st registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
Vor Biopharma · Sites in United States, Georgia
Ages 18–75
National Institute of Dental and Craniofacial Research (NIDCR) · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 36 · Phase 3 14 · Phase 4 3
First in 1984; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 57 across the 76 interventional studies, 220 across the 35 observational. Of the 76 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 111 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 2 studies filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Sjogren's Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT07277257Center For SightEvaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome | 2026-12-31 |
| NCT03276923Duke UniversityMaternal Autoimmune Disease Research Alliance (MADRA) Registry | 2027-01-01 |
| NCT07732582Tufts UniversitySjogren's Mini-Pill Oral and Gut Microbiome Study | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 111 studies in Sjogren's Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).
Other: Placebo · Drug: Standard of Care Treatment
Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).
Drug: Nipocalimab · Drug: Standard of Care Treatment
Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments (\[including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues\], and/or one immunomodulator with or without low-dose glucocorticosteroids).
Drug: Nipocalimab · Drug: Standard of Care Treatment
Placebo infusion will be administered intravenously.
Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
Also known as: JNJ-80202135, M281
Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24
In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement.
Time frame: Baseline (Week 0), Week 24
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24
Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.
Time frame: Baseline (Week 0), Week 24
Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement.
Time frame: Baseline (Week 0), Week 24
Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24
In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement.
Time frame: Baseline (Week 0), Week 24
Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24
Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of \>= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.
Time frame: Baseline (Week 0), Week 24
Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24
Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of \>=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of \>=3 in clinESSDAI score (3), (ii) decrease of \>=1 point or \>=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of \>=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of \>=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of \>=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of \>=25% in rheumatoid factor/decrease of \>=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome).
Time frame: At Week 24
Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24
DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score \* domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of \>= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy).
Time frame: At Week 24
Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24
Percentage of participants with improvement from baseline in \>= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in \>= 3 of the following 5 categories: (i) clinESSDAI score less than (\<) 5 (low disease activity), (ii) decrease of \>= 1 point or \>= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (\<= 5 mm) and an increase of \>= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of \>= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of \>= 25% in rheumatoid factor or decrease of \>= 10% in IgG.
Time frame: At Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment.
Time frame: Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit
Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin \< 20 grams per liter (g/L) (\< 2.0 grams per deciliter \[g/dL\]); applicable to participants who had albumin greater than (\>) 20 g/L at previous assessments. Those who entered with \< 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin \> 20 g/L or those who entered with albumin \< 20g/L and then had an increase in albumin \> 20 g/L which subsequently decreased to \< 20 g/L were reported as an AESI.
Time frame: Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit
A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment.
Time frame: Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit
Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
Time frame: Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (\< 36 degree Celsius and \> 38 degree Celsius), pulse rate (\<= 50 beats per minute \[bpm\] and with \>= 15 bpm decrease from baseline and \>= 120 bpm and with \>= 15 bpm increase from baseline), and blood pressure (systolic blood pressure \[SBP\]: \<= 90 millimeters of mercury \[mmHg\] and with \>= 20 mmHg decrease from baseline and \>= 160 mmHg and with \>= 20 mmHg increase from baseline; diastolic blood pressure \[DBP\]: \<= 50 mmHg and with \>= 15 mmHg decrease from baseline and \>= 100 mmHg and with \>= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported.
Time frame: Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Laboratory parameters included hematology (platelet count \[platelets: decrease \> 20% and value \< 100)\], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential \[lymphocytes: decrease \> 20% and value \< 0.08\], \[leukocytes: decrease \> 10% and value \< 2.5\], \[neutrophils: increase \> 30% and value \> 0.90\], \[eosinophils: increase \> 20% and value \> 0.10\]), serum chemistry (phosphate \[decrease \> 10% and value \< 0.6), lipid panel (high-density lipoprotein \[HDL\] and low-density lipoprotein \[LDL\], creatine kinase: increase \> 20% and value \> 960, cholesterol: value \>= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported.
Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Serum Nipocalimab Concentration Over Time
Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only.
Time frame: Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
Change From Baseline in C-reactive Protein (CRP)
Change from baseline in CRP were reported.
Time frame: Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation.
Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4
Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported.
Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21
Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported.
Time frame: Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
Change From Baseline in Autoantibodies: Rheumatoid Factor (RF)
Change from baseline in autoantibodies included RF were reported.
Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab
Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only.
Time frame: Baseline (Week 0) up to Week 30
Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab
Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only.
Time frame: Baseline (Week 0) up to Week 30
| Milestone | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Started | 56 | 53 | 54 |
| Completed | 46 | 46 | 44 |
| Not completed | 10 | 7 | 10 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 7 | 4 | 7 |
| Withdrew: Other | 0 | 1 | 2 |
In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement.
| Score on a scale | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24 | -3.3 ± 4.72 | -3.8 ± 3.22 | -6.7 ± 4.50 |
Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.
| Scores on a scale | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24 | -1.8 ± 2.01 | -1.2 ± 1.90 | -2.3 ± 1.74 |
ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement.
| Percentage of participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24 | 28.6 | 34.0 | 46.3 |
In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement.
| Percentage of participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24 | 33.9 | 37.7 | 51.9 |
Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of \>= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.
| Percentage of participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24 | 50.0 | 39.6 | 55.6 |
Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of \>=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of \>=3 in clinESSDAI score (3), (ii) decrease of \>=1 point or \>=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of \>=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of \>=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of \>=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of \>=25% in rheumatoid factor/decrease of \>=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome).
| Percentage of participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24 | 39.3 | 50.9 | 63.0 |
DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score \* domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of \>= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy).
| Percentage of participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24 | 33.9 | 52.8 | 53.7 |
Percentage of participants with improvement from baseline in \>= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in \>= 3 of the following 5 categories: (i) clinESSDAI score less than (\<) 5 (low disease activity), (ii) decrease of \>= 1 point or \>= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (\<= 5 mm) and an increase of \>= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of \>= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of \>= 25% in rheumatoid factor or decrease of \>= 10% in IgG.
| Percentage of participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24 | 17.9 | 43.4 | 48.1 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment.
| Participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit | 35 | 42 | 43 |
Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin \< 20 grams per liter (g/L) (\< 2.0 grams per deciliter \[g/dL\]); applicable to participants who had albumin greater than (\>) 20 g/L at previous assessments. Those who entered with \< 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin \> 20 g/L or those who entered with albumin \< 20g/L and then had an increase in albumin \> 20 g/L which subsequently decreased to \< 20 g/L were reported as an AESI.
| Participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit | 1 | 2 | 1 |
A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment.
| Participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit | 3 | 4 | 4 |
Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
| Participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit | 2 | 3 | 3 |
Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (\< 36 degree Celsius and \> 38 degree Celsius), pulse rate (\<= 50 beats per minute \[bpm\] and with \>= 15 bpm decrease from baseline and \>= 120 bpm and with \>= 15 bpm increase from baseline), and blood pressure (systolic blood pressure \[SBP\]: \<= 90 millimeters of mercury \[mmHg\] and with \>= 20 mmHg decrease from baseline and \>= 160 mmHg and with \>= 20 mmHg increase from baseline; diastolic blood pressure \[DBP\]: \<= 50 mmHg and with \>= 15 mmHg decrease from baseline and \>= 100 mmHg and with \>= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported.
| Participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Pulse: =< 50 bpm and with => 15 bpm | 0 | 1 | 0 |
| Pulse:>= 120 bpm and with >= 15 bpm | 0 | 0 | 0 |
| SBP: <= 90 mmHg and with >= 20 mmHg | 3 | 1 | 1 |
| SBP: >= 160 mmHg and with >= 20 mmHg | 0 | 0 | 2 |
| DBP: <= 50 mmHg and with >= 15 mmHg | 1 | 1 | 0 |
| DBP: >= 100 mmHg and with >= 15 mmHg | 0 | 0 | 1 |
| Temperature: < 36 degree Celsius | 5 | 4 | 6 |
| Temperature: > 38 degree Celsius | 0 | 1 | 0 |
Laboratory parameters included hematology (platelet count \[platelets: decrease \> 20% and value \< 100)\], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential \[lymphocytes: decrease \> 20% and value \< 0.08\], \[leukocytes: decrease \> 10% and value \< 2.5\], \[neutrophils: increase \> 30% and value \> 0.90\], \[eosinophils: increase \> 20% and value \> 0.10\]), serum chemistry (phosphate \[decrease \> 10% and value \< 0.6), lipid panel (high-density lipoprotein \[HDL\] and low-density lipoprotein \[LDL\], creatine kinase: increase \> 20% and value \> 960, cholesterol: value \>= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported.
| Participants | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Week 2: Lymphocytes | 1 | 0 | 0 |
| Week 2: Platelets | 1 | 0 | 0 |
| Week 4: Phosphate | 0 | 0 | 1 |
| Week 4: Cholesterol: Value >= 6.2 | 2 | 1 | 1 |
| Week 4: HDL Cholesterol: Value >= 2.1 | 1 | 3 | 7 |
| Week 4: LDL Cholesterol: Value >= 4.1 | 0 | 0 | 1 |
| Week 4: Leukocytes | 1 | 0 | 0 |
| Week 8: Cholesterol: Value >= 6.2 | 1 | 2 | 1 |
| Week 8: HDL Cholesterol: Value >= 2.1 | 2 | 4 | 7 |
| Week 8: LDL Cholesterol: Value >= 4.1 | 0 | 2 | 1 |
| Week 8: Neutrophils | 0 | 1 | 0 |
| Week 8: Lymphocytes | 0 | 2 | 0 |
| Week 12: HDL Cholesterol: Value >= 2.1 | 1 | 3 | 6 |
| Week 12: HDL Cholesterol: Value < 1.0 | 0 | 1 | 0 |
| Week 12: Neutrophils | 0 | 0 | 1 |
| Week 12: Lymphocytes | 0 | 1 | 1 |
| Week 16: Leukocytes | 2 | 0 | 1 |
| Week 24: HDL Cholesterol: Value >= 2.1 | 2 | 4 | 6 |
| Week 24: LDL Cholesterol: Value >= 4.1 | 0 | 2 | 0 |
| Week 24: Eosinophils | 1 | 0 | 0 |
| Week 24: Creatine Kinase | 0 | 1 | 0 |
| Week 24: Cholesterol | 0 | 1 | 0 |
| Week 30: Leukocytes | 0 | 1 | 0 |
| Week 30: Eosinophils | 1 | 0 | 0 |
Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only.
| micrograms per milliliter | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|
| Week 0, predose | 0.000 ± 0.0036 | 0.001 ± 0.0079 |
| Week 0, postdose | 108.132 ± 41.1048 | 354.926 ± 129.2114 |
| Week 2, predose | 0.001 ± 0.0066 | 0.004 ± 0.0145 |
| Week 2, postdose | 98.569 ± 48.0806 | 340.360 ± 130.4009 |
| Week 4, predose | 0.001 ± 0.0046 | 0.001 ± 0.0067 |
| Week 8, predose | 0.002 ± 0.0082 | 0.001 ± 0.0031 |
| Week 8, postdose | 109.944 ± 38.2894 | 345.526 ± 130.7682 |
| Week 12, predose | 0.020 ± 0.1018 | 0.003 ± 0.0119 |
| Week 12, postdose | 107.112 ± 35.8943 | 331.531 ± 187.7316 |
| Week 16, predose | 0.000 ± 0.0000 | 0.004 ± 0.0069 |
| Week 24 | 0.001 ± 0.0026 | 0.003 ± 0.0070 |
| Week 30 | 0.002 ± 0.0066 | 0.000 ± 0.0000 |
Change from baseline in CRP were reported.
| Milligrams per liter | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Week 2 | 1.513 ± 7.6158 | 0.520 ± 6.8520 | 0.939 ± 5.5131 |
| Week 4 | -0.243 ± 2.1402 | 0.238 ± 7.1198 | 0.302 ± 1.9397 |
| Week 6 | -0.279 ± 2.2463 | -0.285 ± 6.7629 | -0.090 ± 2.1916 |
| Week 8 | 0.026 ± 3.3460 | 0.361 ± 2.3499 | -0.121 ± 1.3529 |
| Week 10 | 1.751 ± 1.8643 | 2.242 ± 5.1090 | 1.304 ± 1.3120 |
| Week 12 | 0.918 ± 4.9796 | 0.765 ± 3.2934 | 0.139 ± 2.0962 |
| Week 16 | -0.154 ± 2.1477 | -0.927 ± 7.6604 | 0.107 ± 1.5903 |
| Week 20 | 0.735 ± 6.3374 | 1.020 ± 5.4001 | 0.267 ± 2.9934 |
| Week 24 | 1.524 ± 9.4589 | 1.515 ± 6.6511 | 0.200 ± 1.9106 |
| Week 30 | 0.789 ± 3.8812 | -0.716 ± 6.1862 | -0.176 ± 1.4461 |
Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation.
| Millimeters per hour | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Week 2 | -0.037 ± 14.8768 | 0.100 ± 11.4682 | -6.816 ± 14.6283 |
| Week 4 | -1.340 ± 13.7448 | -1.640 ± 12.3813 | -9.327 ± 16.4929 |
| Week 8 | 10.602 ± 54.9277 | -0.005 ± 114.9206 | -28.010 ± 35.4705 |
| Week 12 | -1.163 ± 17.9691 | -7.932 ± 17.5544 | -11.217 ± 14.6271 |
| Week 16 | -5.213 ± 16.6053 | -7.225 ± 14.7691 | -12.500 ± 15.5616 |
| Week 20 | -9.523 ± 21.9741 | -5.273 ± 16.7726 | -12.390 ± 15.4659 |
| Week 24 | -6.118 ± 19.5332 | -5.261 ± 18.1322 | -9.653 ± 16.5951 |
| Week 30 | -7.478 ± 20.4958 | -2.909 ± 17.3498 | -6.978 ± 19.1115 |
Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported.
| Grams per liter | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| IgG: Week 2 | -0.293 ± 2.5034 | -3.570 ± 1.5226 | -7.712 ± 3.2346 |
| IgG: Week 4 | -0.274 ± 2.6898 | -4.612 ± 1.7211 | -8.904 ± 3.3077 |
| IgG: Week 8 | -0.126 ± 2.6075 | -5.114 ± 1.7088 | -9.578 ± 4.1409 |
| IgG: Week 12 | -0.051 ± 2.6476 | -5.231 ± 1.8415 | -9.899 ± 4.3507 |
| IgG: Week 16 | -0.211 ± 2.9717 | -5.224 ± 2.0568 | -9.340 ± 4.3346 |
| IgG: Week 20 | -0.217 ± 2.6829 | -4.942 ± 2.2000 | -9.976 ± 5.2069 |
| gG: Week 24 | -0.171 ± 3.5555 | -4.360 ± 2.8371 | -9.467 ± 5.4390 |
| IgG: Week 30 | -0.421 ± 4.0162 | -0.015 ± 2.3388 | -0.688 ± 4.9730 |
| IgG1: Week 2 | -0.422 ± 2.4279 | -2.590 ± 1.1672 | -5.720 ± 2.6621 |
| IgG1: Week 4 | -0.256 ± 2.8110 | -3.364 ± 1.8922 | -6.300 ± 2.7080 |
| IgG1: Week 8 | -0.316 ± 2.4727 | -3.444 ± 2.2316 | -6.728 ± 3.0146 |
| IgG1: Week 12 | -0.388 ± 2.6534 | -3.587 ± 2.7108 | -6.997 ± 2.8712 |
| IgG1: Week 16 | -0.155 ± 2.7970 | -3.391 ± 2.7162 | -6.678 ± 3.3193 |
| IgG1: Week 20 | -0.027 ± 2.9349 | -3.547 ± 4.3021 | -7.106 ± 3.1650 |
| IgG1: Week 24 | -0.273 ± 3.4443 | -2.807 ± 3.8918 | -6.854 ± 3.3401 |
| IgG1: Week 30 | -0.567 ± 3.8984 | -0.203 ± 3.9916 | -0.642 ± 4.0439 |
| IgG2: Week 2 | 0.011 ± 0.5523 | -0.478 ± 0.5438 | -1.208 ± 0.8527 |
| IgG2: Week 4 | 0.058 ± 0.5328 | -0.657 ± 0.6511 | -1.471 ± 1.0384 |
| IgG2: Week 8 | -0.025 ± 0.5082 | -0.897 ± 0.6258 | -1.735 ± 1.0015 |
| IgG2: Week 12 | 0.071 ± 0.4862 | -0.893 ± 0.6425 | -1.698 ± 1.0102 |
| IgG2: Week 16 | 0.060 ± 0.5388 | -0.878 ± 0.7311 | -1.655 ± 1.0935 |
| IgG2: Week 20 | 0.043 ± 0.5881 | -0.843 ± 0.7219 | -1.725 ± 1.0670 |
| IgG2: Week 24 | 0.013 ± 0.6359 | -0.786 ± 0.8167 | -1.720 ± 1.0577 |
| IgG2: Week 30 | 0.151 ± 0.6005 | -0.242 ± 0.6325 | -0.600 ± 0.7790 |
| IgG3: Week 2 | -0.021 ± 0.1003 | -0.133 ± 0.1004 | -0.224 ± 0.1398 |
| IgG3: Week 4 | -0.010 ± 0.1030 | -0.148 ± 0.1113 | -0.217 ± 0.1539 |
| IgG3: Week 8 | -0.013 ± 0.0987 | -0.152 ± 0.1266 | -0.217 ± 0.1438 |
| IgG3: Week 12 | -0.002 ± 0.1175 | -0.146 ± 0.1316 | -0.231 ± 0.1396 |
| IgG3: Week 16 | -0.001 ± 0.1234 | -0.145 ± 0.1111 | -0.219 ± 0.1584 |
| IgG3: Week 20 | 0.003 ± 0.1355 | -0.127 ± 0.1705 | -0.236 ± 0.1477 |
| IgG3: Week 24 | -0.006 ± 0.1459 | -0.105 ± 0.1671 | -0.246 ± 0.1656 |
| IgG3: Week 30 | -0.004 ± 0.1334 | -0.012 ± 0.0964 | -0.015 ± 0.0979 |
| IgG4: Week 2 | -0.028 ± 0.1631 | -0.158 ± 0.4306 | -0.242 ± 0.2717 |
| IgG4: Week 4 | -0.001 ± 0.0606 | -0.175 ± 0.4426 | -0.292 ± 0.3429 |
| IgG4: Week 8 | -0.018 ± 0.1231 | -0.207 ± 0.4708 | -0.302 ± 0.3568 |
| IgG4: Week 12 | -0.003 ± 0.1137 | -0.226 ± 0.5036 | -0.317 ± 0.3557 |
| IgG4: Week 16 | -0.010 ± 0.1075 | -0.229 ± 0.5302 | -0.279 ± 0.2811 |
| IgG4: Week 20 | -0.010 ± 0.0923 | -0.227 ± 0.5416 | -0.307 ± 0.3435 |
| IgG4: Week 24 | -0.004 ± 0.0803 | -0.207 ± 0.5828 | -0.308 ± 0.3133 |
| IgG4: Week 30 | -0.008 ± 0.1341 | -0.111 ± 0.5936 | -0.025 ± 0.1846 |
Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported.
| chemiluminescent units (CU) | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Anti-Ro60/SSA: Week 2 | -3.80 (-2480.00 to 893.30) | -3327.70 (-10728.60 to -1492.30) | -6838.30 (-20472.00 to -469.00) |
| Anti-Ro60/SSA: Week 4 | 90.80 (-87.90 to 3520.00) | -5628.70 (-12174.20 to -2884.60) | -8682.45 (-22604.00 to -882.15) |
| Anti-Ro60/SSA: Week 8 | 15.10 (-1480.00 to 1392.00) | -6952.90 (-11828.00 to -2864.25) | -11398.15 (-22522.35 to -925.20) |
| Anti-Ro60/SSA: Week 16 | 41.25 (-2340.20 to 3792.00) | -5424.00 (-8576.00 to -3201.10) | -8511.15 (-20066.55 to -1637.40) |
| Anti-Ro60/SSA: Week 24 | 56.70 (-1787.10 to 2398.90) | -5702.50 (-13240.00 to -804.00) | -8384.40 (-18053.85 to -619.55) |
| Anti-Ro60/SSA: Week 30 | -13.80 (-3208.15 to 2681.85) | -73.60 (-2270.60 to 773.25) | -39.90 (-2006.70 to 5976.00) |
| Anti-Ro52/TRIM21: Week 2 | -0.50 (-181.60 to 26.00) | -490.80 (-1877.50 to -107.40) | -496.30 (-1988.40 to 0.00) |
| Anti-Ro52/TRIM21: Week 4 | -0.45 (-170.20 to 24.40) | -762.50 (-2876.90 to -277.25) | -523.90 (-2412.50 to -24.70) |
| Anti-Ro52/TRIM21: Week 8 | -1.30 (-880.30 to 7.00) | -732.60 (-1943.40 to -272.80) | -611.40 (-3042.30 to 0.00) |
| Anti-Ro52/TRIM21: Week 16 | -0.05 (-430.60 to 253.80) | -581.90 (-1741.30 to -249.10) | -592.10 (-2494.10 to -21.90) |
| Anti-Ro52/TRIM21: Week 24 | 0.60 (-36.90 to 1098.10) | -525.95 (-1488.90 to -29.20) | -493.20 (-1397.60 to 0.00) |
| Anti-Ro52/TRIM21: Week 30 | 0.00 (-1031.80 to 184.40) | 0.90 (-233.80 to 768.00) | 0.00 (-167.75 to 507.75) |
| Anti-La/SSB: Week 2 | 0.00 (-3.70 to 6.00) | -19.40 (-134.90 to -3.20) | -25.30 (-346.10 to -2.60) |
| Anti-La/SSB: Week 4 | 0.00 (-3.80 to 10.20) | -33.80 (-179.70 to -6.70) | -38.90 (-369.90 to -6.00) |
| Anti-La/SSB: Week 8 | -0.15 (-18.45 to 7.00) | -27.25 (-122.40 to -5.40) | -44.60 (-507.90 to -5.20) |
| Anti-La/SSB: Week 16 | 0.00 (-3.60 to 56.50) | -28.10 (-323.30 to -1.30) | -46.50 (-530.50 to -9.20) |
| Anti-La/SSB: Week 24 | 1.10 (-5.35 to 53.10) | -22.30 (-318.20 to 0.00) | -40.80 (-2861.40 to -6.20) |
| Anti-La/SSB: Week 30 | 0.00 (-19.30 to 29.00) | -1.40 (-29.60 to 6.80) | -3.65 (-43.25 to 0.00) |
Change from baseline in autoantibodies included RF were reported.
| international unit per millilitre | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|---|
| Week 2 | -0.500 (-2.200 to 0.000) | -1.700 (-4.500 to 0.000) | -3.600 (-9.500 to 0.000) |
| Week 4 | -0.150 (-2.500 to 0.400) | -3.300 (-6.600 to -0.600) | -5.400 (-14.500 to -0.500) |
| Week 8 | -0.100 (-1.600 to 1.000) | -3.200 (-6.000 to 0.000) | -4.400 (-14.100 to 0.000) |
| Week 12 | 0.000 (-1.500 to 3.400) | -2.700 (-4.700 to 0.000) | -5.650 (-16.800 to -0.500) |
| Week 16 | 0.000 (-2.250 to 2.350) | -3.450 (-6.900 to 0.000) | -6.000 (-18.600 to -0.500) |
| Week 20 | 0.000 (-3.000 to 2.500) | -2.900 (-5.900 to 0.000) | -6.900 (-18.600 to 0.000) |
| Week 24 | 0.000 (-1.700 to 1.400) | -2.850 (-5.950 to 0.000) | -4.400 (-16.000 to 0.000) |
| Week 30 | 0.000 (-3.300 to 1.700) | 0.000 (-1.800 to 3.450) | 0.000 (-1.800 to 1.600) |
Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only.
| Participants | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab | 46 | 41 |
Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only.
| Participants | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w |
|---|---|---|
| Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab | 33 | 28 |
Collected over All-cause mortality: From screening (Week -6) up to Week 30; Serious and Other AEs: Post first administration of study intervention (Week 0) up to Week 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Placebo IV q2w | 0/56 (0%) | 3/56 (5.4%) | 22/56 (39.3%) |
| Group 2: Nipocalimab 5 mg/kg q2w | 0/53 (0%) | 4/53 (7.5%) | 35/53 (66%) |
| Group 3: Nipocalimab 15 mg/kg q2w | 0/54 (0%) | 4/54 (7.4%) | 32/54 (59.3%) |
| Event | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg q2w | Group 3: Nipocalimab 15 mg/kg q2w |
|---|---|---|---|
| Anaphylactic ReactionImmune system disorders | 0/56 | 1/53 | 0/54 |
| AppendicitisInfections and infestations | 0/56 | 1/53 | 0/54 |
| Covid-19Infections and infestations | 0/56 | 1/53 | 0/54 |
| ErythemaSkin and subcutaneous tissue disorders | 0/56 | 1/53 | 0/54 |
| Genital Herpes SimplexInfections and infestations | 0/56 | 0/53 | 1/54 |
| Anembryonic GestationPregnancy, puerperium and perinatal conditions | 0/56 | 0/53 | 1/54 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/56 | 0/53 | 1/54 |
| Pulmonary MassRespiratory, thoracic and mediastinal disorders | 0/56 | 0/53 | 1/54 |
| Cardiac Failure CongestiveCardiac disorders | 1/56 | 0/53 | 0/54 |
| Acute SinusitisInfections and infestations | 1/56 | 0/53 | 0/54 |
| Event | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg q2w | Group 3: Nipocalimab 15 mg/kg q2w |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 2/56 | 3/53 | 8/54 |
| HeadacheNervous system disorders | 8/56 | 4/53 | 6/54 |
| Covid-19Infections and infestations | 3/56 | 7/53 | 3/54 |
| NasopharyngitisInfections and infestations | 4/56 | 4/53 | 7/54 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/56 | 6/53 | 3/54 |
| NauseaGastrointestinal disorders | 2/56 | 0/53 | 6/54 |
| FatigueGeneral disorders | 6/56 | 3/53 | 6/54 |
| Abdominal Pain UpperGastrointestinal disorders | 2/56 | 4/53 | 1/54 |
| ConjunctivitisInfections and infestations | 3/56 | 4/53 | 1/54 |
| Urinary Tract InfectionInfections and infestations | 3/56 | 4/53 | 3/54 |
| Age, Categorical(Participants) | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 50 | 49 | 48 | 147 |
| >=65 years | 6 | 4 | 6 | 16 |
| Age, Continuous(years) | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w | Total |
|---|---|---|---|---|
| Mean | 47.3 ± 12.6 | 48.3 ± 11.83 | 48.6 ± 12.07 | 48.1 ± 12.12 |
| Sex: Female, Male(Participants) | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w | Total |
|---|---|---|---|---|
| Female | 52 | 49 | 50 | 151 |
| Male | 4 | 4 | 4 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 3 |
| Not Hispanic or Latino | 55 | 53 | 52 | 160 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 5 | 3 | 4 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 50 | 49 | 49 | 148 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Group 1: Placebo IV q2w | Group 2: Nipocalimab 5 mg/kg IV q2w | Group 3: Nipocalimab 15 mg/kg IV q2w | Total |
|---|---|---|---|---|
| France | 1 | 0 | 2 | 3 |
| Germany | 10 | 12 | 8 | 30 |
| Italy | 0 | 1 | 0 | 1 |
| Japan | 2 | 3 | 2 | 7 |
| Poland | 30 | 30 | 30 | 90 |
| Portugal | 0 | 0 | 1 | 1 |
| Spain | 1 | 0 | 1 | 2 |
| Taiwan | 3 | 0 | 1 | 4 |
| United States | 9 | 7 | 9 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Data sharing details ↗ · innovativemedicine.jnj.com
Ran from Sep 2021 to primary completion in Oct 2023, 25 months.
Results were first posted in Nov 2026, 3 years after primary completion. A results delay was requested in Oct 2024.
Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 25 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nipocalimab
Janssen Research & Development, LLC →